DE69331911T2 - Diagnose mittels signalverstärkung durch ein ribozym - Google Patents

Diagnose mittels signalverstärkung durch ein ribozym

Info

Publication number
DE69331911T2
DE69331911T2 DE69331911T DE69331911T DE69331911T2 DE 69331911 T2 DE69331911 T2 DE 69331911T2 DE 69331911 T DE69331911 T DE 69331911T DE 69331911 T DE69331911 T DE 69331911T DE 69331911 T2 DE69331911 T2 DE 69331911T2
Authority
DE
Germany
Prior art keywords
target
ribozyme
bound
molecule
image
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69331911T
Other languages
English (en)
Other versions
DE69331911D1 (de
Inventor
Andy Shih
M Bockman
T George
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Sirna Therapeutics Inc
Original Assignee
Yale University
Ribozyme Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University, Ribozyme Pharmaceuticals Inc filed Critical Yale University
Application granted granted Critical
Publication of DE69331911D1 publication Critical patent/DE69331911D1/de
Publication of DE69331911T2 publication Critical patent/DE69331911T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6816—Hybridisation assays characterised by the detection means
    • C12Q1/6823—Release of bound markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/121—Hammerhead
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3517—Marker; Tag
DE69331911T 1992-12-04 1993-12-03 Diagnose mittels signalverstärkung durch ein ribozym Expired - Lifetime DE69331911T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98530892A 1992-12-04 1992-12-04
PCT/US1993/011775 WO1994013833A1 (en) 1992-12-04 1993-12-03 Ribozyme amplified diagnostics

Publications (2)

Publication Number Publication Date
DE69331911D1 DE69331911D1 (de) 2002-06-13
DE69331911T2 true DE69331911T2 (de) 2002-11-21

Family

ID=25531365

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69331911T Expired - Lifetime DE69331911T2 (de) 1992-12-04 1993-12-03 Diagnose mittels signalverstärkung durch ein ribozym

Country Status (8)

Country Link
US (1) US5589332A (de)
EP (2) EP0681613B1 (de)
JP (2) JP3595841B2 (de)
AT (1) ATE217347T1 (de)
AU (1) AU675482B2 (de)
DE (1) DE69331911T2 (de)
ES (1) ES2176233T3 (de)
WO (1) WO1994013833A1 (de)

Families Citing this family (167)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040127446A1 (en) * 1992-05-14 2004-07-01 Lawrence Blatt Oligonucleotide mediated inhibition of hepatitis B virus and hepatitis C virus replication
WO2002081494A1 (en) * 2001-03-26 2002-10-17 Sirna Therapeutics, Inc. Oligonucleotide mediated inhibition of hepatitis b virus and hepatitis c virus replication
US20030125270A1 (en) * 2000-12-18 2003-07-03 Lawrence Blatt Enzymatic nucleic acid treatment of diseases or conditions related to hepatitis C virus infection
US5599704A (en) * 1992-08-26 1997-02-04 Ribozyme Pharmaceuticals, Inc. ErbB2/neu targeted ribozymes
AU692816B2 (en) * 1993-07-19 1998-06-18 Gen-Probe Incorporated Oligonucleotide screening assay
AU692212B2 (en) * 1993-12-17 1998-06-04 Roger S. Cubicciotti Nucleotide-directed assembly of bimolecular and multimolecular drugs and devices
US5869248A (en) * 1994-03-07 1999-02-09 Yale University Targeted cleavage of RNA using ribonuclease P targeting and cleavage sequences
US5998193A (en) * 1994-06-24 1999-12-07 Gene Shears Pty., Ltd. Ribozymes with optimized hybridizing arms, stems, and loops, tRNA embedded ribozymes and compositions thereof
US6057153A (en) * 1995-01-13 2000-05-02 Yale University Stabilized external guide sequences
US6214546B1 (en) 1995-02-27 2001-04-10 Intelligene Ltd. Detection of biomolecules
AU697317B2 (en) * 1995-02-27 1998-10-01 Intelligene Ltd. Detection of biomolecules
US7034009B2 (en) * 1995-10-26 2006-04-25 Sirna Therapeutics, Inc. Enzymatic nucleic acid-mediated treatment of ocular diseases or conditions related to levels of vascular endothelial growth factor receptor (VEGF-R)
US20040102389A1 (en) * 1995-10-26 2004-05-27 Ribozyme Pharmaceuticals, Inc. Nucleic acid-mediated treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor (VEGF-R)
US20040220128A1 (en) * 1995-10-26 2004-11-04 Sirna Therapeutics, Inc. Nucleic acid based modulation of female reproductive diseases and conditions
US20040142895A1 (en) * 1995-10-26 2004-07-22 Sirna Therapeutics, Inc. Nucleic acid-based modulation of gene expression in the vascular endothelial growth factor pathway
US5985557A (en) * 1996-01-24 1999-11-16 Third Wave Technologies, Inc. Invasive cleavage of nucleic acids
EP0904286A4 (de) * 1996-01-24 2004-01-14 Third Wave Tech Inc Invasive spaltung von nukleinsäuren
US5877162A (en) * 1996-03-14 1999-03-02 Innovir Laboratories, Inc. Short external guide sequences
WO1997047768A1 (en) * 1996-06-10 1997-12-18 Fenggang Wang Method for randomly synthesizing biopolymers
CA2264246A1 (en) * 1996-08-26 1998-03-05 Intelligene Ltd. Catalytic nucleic acid and its medical use
CA2275541A1 (en) * 1996-12-19 1998-06-25 Yale University Bioreactive allosteric polynucleotides
US20030186909A1 (en) * 1997-01-27 2003-10-02 Ribozyme Pharmaceuticals, Inc. Nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors
EP3034626A1 (de) * 1997-04-01 2016-06-22 Illumina Cambridge Limited Verfahren zur vervielfältigung von nukleinsäuren
US6194149B1 (en) * 1998-03-03 2001-02-27 Third Wave Technologies, Inc. Target-dependent reactions using structure-bridging oligonucleotides
CA2300938A1 (en) * 1997-08-20 1999-02-25 Somagenics, Inc. Antisense and antigene therapeutics with improved binding properties and methods for their use
US6482932B1 (en) 1997-11-05 2002-11-19 Ribozyme Pharmaceuticals, Incorporated Nucleoside triphosphates and their incorporation into oligonucleotides
US6617438B1 (en) 1997-11-05 2003-09-09 Sirna Therapeutics, Inc. Oligoribonucleotides with enzymatic activity
EP1053317B1 (de) 1998-02-13 2006-11-02 Köster, Hubert Verwendung von ribozymen zur bestimmung der funktion von genen
KR100748863B1 (ko) * 1998-03-05 2007-08-13 존슨 앤드 존슨 리서치 피티와이 리미티드 효소원 핵산 검출 방법, 및 관련 분자 및 키트
WO1999053031A2 (en) * 1998-04-08 1999-10-21 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Process for producing cell clone libraries
US6287765B1 (en) 1998-05-20 2001-09-11 Molecular Machines, Inc. Methods for detecting and identifying single molecules
IL126732A0 (en) * 1998-10-23 1999-08-17 Intelligene Ltd Pro drug
IL126731A0 (en) * 1998-10-23 1999-08-17 Intelligene Ltd A method of detection
US6995259B1 (en) * 1998-10-23 2006-02-07 Sirna Therapeutics, Inc. Method for the chemical synthesis of oligonucleotides
DE19915141C2 (de) * 1999-03-26 2002-11-21 Artus Ges Fuer Molekularbiolog Detektion von Nucleinsäure-Amplifikaten
IL130606A0 (en) * 1999-06-23 2000-06-01 Intelligene Ltd An array of nucleic acid sequence
IL132710A0 (en) * 1999-11-02 2001-03-19 Intelligene Ltd Catalytic nucleic acid sequences
US7491805B2 (en) * 2001-05-18 2009-02-17 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
US7833992B2 (en) * 2001-05-18 2010-11-16 Merck Sharpe & Dohme Conjugates and compositions for cellular delivery
US20070026394A1 (en) * 2000-02-11 2007-02-01 Lawrence Blatt Modulation of gene expression associated with inflammation proliferation and neurite outgrowth using nucleic acid based technologies
US8202979B2 (en) * 2002-02-20 2012-06-19 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
JP2003525037A (ja) * 2000-02-11 2003-08-26 リボザイム・ファーマシューティカルズ・インコーポレーテッド Ｃｄ２０およびｎｏｇｏ遺伝子発現の調節および診断のための方法および試薬
US20040009510A1 (en) * 2000-03-06 2004-01-15 Scott Seiwert Allosteric nucleic acid sensor molecules
US20030065155A1 (en) * 2000-03-06 2003-04-03 Nassim Usman Nucleic acid sensor molecules
US20040023292A1 (en) * 2001-10-19 2004-02-05 Mcswiggen James Method and reagent for the detection of proteins and peptides
EP1263947A2 (de) * 2000-03-06 2002-12-11 Ribozyme Pharmaceuticals, Inc. Nukleinsäure sensormoleküle
EP1364009A2 (de) * 2000-06-15 2003-11-26 Board of Regents, The University of Texas System Regulierbare, katalytisch-aktive nukleinsäuren
WO2001096541A2 (en) * 2000-06-15 2001-12-20 Board Of Regents Allosterically regulated ribozymes
US20080032942A1 (en) * 2000-08-30 2008-02-07 Mcswiggen James RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA)
US20050209179A1 (en) * 2000-08-30 2005-09-22 Sirna Therapeutics, Inc. RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA)
US7125660B2 (en) * 2000-09-13 2006-10-24 Archemix Corp. Nucleic acid sensor molecules and methods of using same
AR031640A1 (es) * 2000-12-08 2003-09-24 Applied Research Systems Amplificacion isotermica de acidos nucleicos en un soporte solido
US7517864B2 (en) * 2001-05-18 2009-04-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20050222066A1 (en) * 2001-05-18 2005-10-06 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20040209831A1 (en) * 2002-02-20 2004-10-21 Mcswiggen James RNA interference mediated inhibition of hepatitis C virus (HCV) gene expression using short interfering nucleic acid (siNA)
US20050159379A1 (en) * 2001-05-18 2005-07-21 Sirna Therapeutics, Inc RNA interference mediated inhibition of gastric inhibitory polypeptide (GIP) and gastric inhibitory polypeptide receptor (GIPR) gene expression using short interfering nucleic acid (siNA)
US20050287128A1 (en) * 2001-05-18 2005-12-29 Sirna Therapeutics, Inc. RNA interference mediated inhibition of TGF-beta and TGF-beta receptor gene expression using short interfering nucleic acid (siNA)
US20050227935A1 (en) * 2001-05-18 2005-10-13 Sirna Therapeutics, Inc. RNA interference mediated inhibition of TNF and TNF receptor gene expression using short interfering nucleic acid (siNA)
US20050233344A1 (en) * 2001-05-18 2005-10-20 Sirna Therapeutics, Inc. RNA interference mediated inhibition of platelet derived growth factor (PDGF) and platelet derived growth factor receptor (PDGFR) gene expression using short interfering nucleic acid (siNA)
US20050191638A1 (en) * 2002-02-20 2005-09-01 Sirna Therapeutics, Inc. RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA)
US20050196767A1 (en) * 2001-05-18 2005-09-08 Sirna Therapeutics, Inc. RNA interference mediated inhibition of GRB2 associated binding protein (GAB2) gene expression using short interfering nucleic acis (siNA)
US20050203040A1 (en) * 2001-05-18 2005-09-15 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular cell adhesion molecule (VCAM) gene expression using short interfering nucleic acid (siNA)
US20050153914A1 (en) * 2001-05-18 2005-07-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of MDR P-glycoprotein gene expression using short interfering nucleic acid (siNA)
US7109165B2 (en) * 2001-05-18 2006-09-19 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
US9994853B2 (en) 2001-05-18 2018-06-12 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
US20050136436A1 (en) * 2001-05-18 2005-06-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of G72 and D-amino acid oxidase (DAAO) gene expression using short interfering nucleic acid (siNA)
US20080188430A1 (en) * 2001-05-18 2008-08-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of hypoxia inducible factor 1 (HIF1) gene expression using short interfering nucleic acid (siNA)
US20050164967A1 (en) * 2001-05-18 2005-07-28 Sirna Therapeutics, Inc. RNA interference mediated inhibition of platelet-derived endothelial cell growth factor (ECGF1) gene expression using short interfering nucleic acid (siNA)
US20050159382A1 (en) * 2001-05-18 2005-07-21 Sirna Therapeutics, Inc. RNA interference mediated inhibition of polycomb group protein EZH2 gene expression using short interfering nucleic acid (siNA)
US20050187174A1 (en) * 2001-05-18 2005-08-25 Sirna Therapeutics, Inc. RNA interference mediated inhibition of intercellular adhesion molecule (ICAM) gene expression using short interfering nucleic acid (siNA)
US20050124568A1 (en) * 2001-05-18 2005-06-09 Sirna Therapeutics, Inc. RNA interference mediated inhibition of acetyl-CoA-carboxylase gene expression using short interfering nucleic acid (siNA)
US20050159380A1 (en) * 2001-05-18 2005-07-21 Sirna Therapeutics, Inc. RNA interference mediated inhibition of angiopoietin gene expression using short interfering nucleic acid (siNA)
US20050182006A1 (en) * 2001-05-18 2005-08-18 Sirna Therapeutics, Inc RNA interference mediated inhibition of protein kinase C alpha (PKC-alpha) gene expression using short interfering nucleic acid (siNA)
US20060211642A1 (en) * 2001-05-18 2006-09-21 Sirna Therapeutics, Inc. RNA inteference mediated inhibition of hepatitis C virus (HVC) gene expression using short interfering nucleic acid (siNA)
US20050159376A1 (en) * 2002-02-20 2005-07-21 Slrna Therapeutics, Inc. RNA interference mediated inhibition 5-alpha reductase and androgen receptor gene expression using short interfering nucleic acid (siNA)
US20060142225A1 (en) * 2001-05-18 2006-06-29 Sirna Therapeutics, Inc. RNA interference mediated inhibition of cyclin dependent kinase-2 (CDK2) gene expression using short interfering nucleic acid (siNA)
US20050119211A1 (en) * 2001-05-18 2005-06-02 Sirna Therapeutics, Inc. RNA mediated inhibition connexin gene expression using short interfering nucleic acid (siNA)
US20030130186A1 (en) * 2001-07-20 2003-07-10 Chandra Vargeese Conjugates and compositions for cellular delivery
US20050233997A1 (en) * 2001-05-18 2005-10-20 Sirna Therapeutics, Inc. RNA interference mediated inhibition of matrix metalloproteinase 13 (MMP13) gene expression using short interfering nucleic acid (siNA)
US20050182009A1 (en) * 2001-05-18 2005-08-18 Sirna Therapeutics, Inc. RNA interference mediated inhibition of NF-Kappa B / REL-A gene expression using short interfering nucleic acid (siNA)
US20050164966A1 (en) * 2001-05-18 2005-07-28 Sirna Therapeutics, Inc. RNA interference mediated inhibition of type 1 insulin-like growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20050233996A1 (en) * 2002-02-20 2005-10-20 Sirna Therapeutics, Inc. RNA interference mediated inhibition of hairless (HR) gene expression using short interfering nucleic acid (siNA)
US20050080031A1 (en) * 2001-05-18 2005-04-14 Sirna Therapeutics, Inc. Nucleic acid treatment of diseases or conditions related to levels of Ras, HER2 and HIV
US20060019913A1 (en) * 2001-05-18 2006-01-26 Sirna Therapeutics, Inc. RNA interference mediated inhibtion of protein tyrosine phosphatase-1B (PTP-1B) gene expression using short interfering nucleic acid (siNA)
US20050137155A1 (en) * 2001-05-18 2005-06-23 Sirna Therapeutics, Inc. RNA interference mediated treatment of Parkinson disease using short interfering nucleic acid (siNA)
US20050014172A1 (en) * 2002-02-20 2005-01-20 Ivan Richards RNA interference mediated inhibition of muscarinic cholinergic receptor gene expression using short interfering nucleic acid (siNA)
US20050182007A1 (en) * 2001-05-18 2005-08-18 Sirna Therapeutics, Inc. RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA)
US20060142226A1 (en) * 2001-05-18 2006-06-29 Sirna Therapeutics, Inc. RNA interference mediated inhibition of cholesteryl ester transfer protein (CETP) gene expression using short interfering nucleic acid (siNA)
US20050164224A1 (en) * 2001-05-18 2005-07-28 Sirna Therapeutics, Inc. RNA interference mediated inhibition of cyclin D1 gene expression using short interfering nucleic acid (siNA)
US20050196765A1 (en) * 2001-05-18 2005-09-08 Sirna Therapeutics, Inc. RNA interference mediated inhibition of checkpoint Kinase-1 (CHK-1) gene expression using short interfering nucleic acid (siNA)
US20050176664A1 (en) * 2001-05-18 2005-08-11 Sirna Therapeutics, Inc. RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering nucleic acid (siNA)
US20050054598A1 (en) * 2002-02-20 2005-03-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition hairless (HR) gene expression using short interfering nucleic acid (siNA)
US20050176666A1 (en) * 2001-05-18 2005-08-11 Sirna Therapeutics, Inc. RNA interference mediated inhibition of GPRA and AAA1 gene expression using short interfering nucleic acid (siNA)
EP1572067A4 (de) 2001-05-18 2009-05-13 Sirna Therapeutics Inc Konjugate und zusammensetzungen für die zelluläre freisetzung
US20050143333A1 (en) * 2001-05-18 2005-06-30 Sirna Therapeutics, Inc. RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA)
US20050164968A1 (en) * 2001-05-18 2005-07-28 Sirna Therapeutics, Inc. RNA interference mediated inhibition of ADAM33 gene expression using short interfering nucleic acid (siNA)
US20040006035A1 (en) * 2001-05-29 2004-01-08 Dennis Macejak Nucleic acid mediated disruption of HIV fusogenic peptide interactions
US20050124566A1 (en) * 2001-05-18 2005-06-09 Sirna Therapeutics, Inc. RNA interference mediated inhibition of myostatin gene expression using short interfering nucleic acid (siNA)
US20050209180A1 (en) * 2001-05-18 2005-09-22 Sirna Therapeutics, Inc. RNA interference mediated inhibition of hepatitis C virus (HCV) expression using short interfering nucleic acid (siNA)
US20050079610A1 (en) * 2001-05-18 2005-04-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of Fos gene expression using short interfering nucleic acid (siNA)
US20050153915A1 (en) * 2001-05-18 2005-07-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of early growth response gene expression using short interfering nucleic acid (siNA)
US20050119212A1 (en) * 2001-05-18 2005-06-02 Sirna Therapeutics, Inc. RNA interference mediated inhibition of FAS and FASL gene expression using short interfering nucleic acid (siNA)
US20050124567A1 (en) * 2001-05-18 2005-06-09 Sirna Therapeutics, Inc. RNA interference mediated inhibition of TRPM7 gene expression using short interfering nucleic acid (siNA)
US20050130181A1 (en) * 2001-05-18 2005-06-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of wingless gene expression using short interfering nucleic acid (siNA)
US20050256068A1 (en) * 2001-05-18 2005-11-17 Sirna Therapeutics, Inc. RNA interference mediated inhibition of stearoyl-CoA desaturase (SCD) gene expression using short interfering nucleic acid (siNA)
US20080161256A1 (en) * 2001-05-18 2008-07-03 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
EP1390472A4 (de) * 2001-05-29 2004-11-17 Sirna Therapeutics Inc Nukleinsäurebehandlung von krankheiten oder leiden im zusammenhang mit ras-, her2- und hiv-niveaus
US20030140362A1 (en) * 2001-06-08 2003-07-24 Dennis Macejak In vivo models for screening inhibitors of hepatitis B virus
US7205399B1 (en) 2001-07-06 2007-04-17 Sirna Therapeutics, Inc. Methods and reagents for oligonucleotide synthesis
AU2002313699A1 (en) * 2001-07-20 2003-03-03 Ribozyme Pharmacuticals, Inc. Enzymatic nucleic acid peptide conjugates
WO2003014375A2 (en) * 2001-08-09 2003-02-20 Archemix Corporation Nucleic acid sensor molecules and methods of using same
EP1430150B1 (de) 2001-09-24 2015-08-19 One Lambda, Inc. Diagnostisches sondennachweissystem
AU2002357240A1 (en) * 2001-12-14 2003-06-30 Yale University Nucleic acid diagnostic reagents and methods for detecting nucleic acids, polynucleotides and oligonucleotides
AU2003208959A1 (en) * 2002-01-30 2003-09-02 Id Biomedical Corporation Methods for detecting vancomycin-resistant microorganisms and compositions therefor
US7071311B2 (en) * 2002-02-13 2006-07-04 Sirna Therapeutics, Inc. Antibodies having specificity for 2′-C-allyl nucleic acids
US20050042632A1 (en) * 2002-02-13 2005-02-24 Sirna Therapeutics, Inc. Antibodies having specificity for nucleic acids
US20050222064A1 (en) * 2002-02-20 2005-10-06 Sirna Therapeutics, Inc. Polycationic compositions for cellular delivery of polynucleotides
WO2003106476A1 (en) * 2002-02-20 2003-12-24 Sirna Therapeutics, Inc Nucleic acid mediated inhibition of enterococcus infection and cytolysin toxin activity
US20050137153A1 (en) * 2002-02-20 2005-06-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of alpha-1 antitrypsin (AAT) gene expression using short interfering nucleic acid (siNA)
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US20050096284A1 (en) * 2002-02-20 2005-05-05 Sirna Therapeutics, Inc. RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA)
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US20040018515A1 (en) * 2002-04-03 2004-01-29 Diener John L. Compositions selective for adenosine diphosphate and methods of using same
US20030228603A1 (en) * 2002-04-05 2003-12-11 Cload Sharon T. Compositions selective for caffeine or aspartame and methods of using same
US20030224435A1 (en) * 2002-05-16 2003-12-04 Scott Seiwert Detection of abused substances and their metabolites using nucleic acid sensor molecules
EP2292801B1 (de) 2002-06-14 2018-08-08 Gen-Probe Incorporated Zusammensetzungen und verfahren zur detektion des hepatitis-b-virus
WO2003106659A2 (en) * 2002-06-18 2003-12-24 Archemix Corp. Aptamer-toxin molecules and methods for using same
US20040249130A1 (en) * 2002-06-18 2004-12-09 Martin Stanton Aptamer-toxin molecules and methods for using same
CA2492463A1 (en) 2002-07-25 2004-02-05 Archemix Corporation Regulated aptamer therapeutics
US20040137429A1 (en) * 2002-10-02 2004-07-15 David Epstein Therapeutic aptamers having binding specificity to gp41 of HIV
US20040253243A1 (en) * 2003-01-21 2004-12-16 David Epstein Aptamer therapeutics useful in ocular pharmacotherapy
US8039443B2 (en) * 2002-11-21 2011-10-18 Archemix Corporation Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
US8853376B2 (en) 2002-11-21 2014-10-07 Archemix Llc Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
US20050124565A1 (en) * 2002-11-21 2005-06-09 Diener John L. Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
US10100316B2 (en) * 2002-11-21 2018-10-16 Archemix Llc Aptamers comprising CPG motifs
US20050037394A1 (en) * 2002-12-03 2005-02-17 Keefe Anthony D. Method for in vitro selection of 2'-substituted nucleic acids
ES2428628T3 (es) * 2002-12-12 2013-11-08 Novartis Vaccines And Diagnostics, Inc. Dispositivo y método para pruebas de sangre en línea usando biochips
US20030232400A1 (en) * 2002-12-20 2003-12-18 Susan Radka Methods of screening subjects for expression of soluble receptors of vascular endothelial growth factor (VEGF) for use in managing treatment and determining prognostic outcome
US20040231231A1 (en) * 2002-12-20 2004-11-25 Cataldo Dominic A. Use of colloidal clays for sustained release of active ingredients
EP1622572B1 (de) 2003-04-30 2017-12-20 Sirna Therapeutics, Inc. Konjugate und zusammensetzungen für die zelluläre abgabe
EP1717313A4 (de) * 2003-09-22 2007-11-14 Univ Kyoto Nukleinsäuresonde, nukleinsäurechip, verfahren zum nachweis einer zielnukleinsäure, wirkstoff-screening-verfahren, vorrichtung zum nachweis einer zielnukleinsäure und gendiagnoseverfahren
US20070254282A1 (en) * 2004-01-29 2007-11-01 Yissum Research And Development Company Of The Hebrew University Of Jerusalem Catalytic Polynucleotide and Its Use for Determination of Analytes
US10508277B2 (en) 2004-05-24 2019-12-17 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
US20090176725A1 (en) * 2005-08-17 2009-07-09 Sirna Therapeutics Inc. Chemically modified short interfering nucleic acid molecules that mediate rna interference
KR101379621B1 (ko) * 2005-10-07 2014-04-11 존슨 앤드 존슨 리서치 피티와이 리미티드 다성분 핵산 효소 및 이의 사용 방법
GB0522310D0 (en) 2005-11-01 2005-12-07 Solexa Ltd Methods of preparing libraries of template polynucleotides
GB0524069D0 (en) * 2005-11-25 2006-01-04 Solexa Ltd Preparation of templates for solid phase amplification
US8097425B2 (en) * 2006-03-10 2012-01-17 Tethys Bioscience, Inc. Multiplex protein fractionation
EP2021503A1 (de) * 2006-03-17 2009-02-11 Solexa Ltd. Isothermische methoden zur entstehung von arrays von einzelnen molekülen
US7955443B2 (en) 2006-04-14 2011-06-07 Shin-Etsu Chemical Co., Ltd. Method for preparing rare earth permanent magnet material
WO2007130493A2 (en) 2006-05-03 2007-11-15 Regents Of The University Of Colorado Cd40 agonist antibody/type1 interferon synergistic adjuvant combination, conjugates containing and use thereof as a therapeutic to enhance cellular immunity
EP2471815B1 (de) 2006-07-11 2016-03-30 University Of Medicine And Dentistry Of New Jersey Proteine, Nukleinsäuren zu deren Kodierung und entsprechende Verwendungsverfahren
CA2663164C (en) * 2006-10-06 2016-07-12 Johnson & Johnson Research Pty Limited Molecular switches and methods for their use
WO2008093098A2 (en) 2007-02-02 2008-08-07 Illumina Cambridge Limited Methods for indexing samples and sequencing multiple nucleotide templates
JP2010523088A (ja) * 2007-04-05 2010-07-15 ジョンソン アンド ジョンソン リサーチ ピーティーワイ リミテッド 核酸酵素および複合体ならびにそれらの使用方法
WO2010038042A1 (en) 2008-10-02 2010-04-08 Illumina Cambridge Ltd. Nucleic acid sample enrichment for sequencing applications
US20100305197A1 (en) * 2009-02-05 2010-12-02 Massachusetts Institute Of Technology Conditionally Active Ribozymes And Uses Thereof
US8182994B2 (en) 2009-09-15 2012-05-22 Illumina Cambridge Limited Centroid markers for image analysis of high denisty clusters in complex polynucleotide sequencing
JP2013515693A (ja) 2009-12-23 2013-05-09 ノバルティス アーゲー 脂質、脂質組成物およびそれらの使用方法
EP2632472B1 (de) 2010-10-29 2017-12-13 Sirna Therapeutics, Inc. Durch rna-interferenz vermittelte inhibition einer genexpression unter verwendung von short-interfering-nukleinsäuren (sina)
US10124065B2 (en) 2013-03-08 2018-11-13 Novartis Ag Lipids and lipid compositions for the delivery of active agents
ES2774968T3 (es) 2013-12-19 2020-07-23 Novartis Ag Lípidos y composiciones lipídicas para la administración de agentes activos
ES2908827T3 (es) 2013-12-19 2022-05-04 Novartis Ag Lípidos y composiciones lipídicas para el suministro de agentes activos
JP6778175B2 (ja) 2014-07-16 2020-10-28 ノバルティス アーゲー 脂質ナノ粒子ホスト中に核酸を封入する方法
US10125092B2 (en) 2014-09-05 2018-11-13 Novartis Ag Lipids and lipid compositions for the delivery of active agents
US10934549B2 (en) 2017-08-18 2021-03-02 University Of Iowa Research Foundation Nucleic acid aptamers
WO2020023741A1 (en) * 2018-07-25 2020-01-30 Ohio State Innovation Foundation Large scale production of rna particles

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775619A (en) * 1984-10-16 1988-10-04 Chiron Corporation Polynucleotide determination with selectable cleavage sites
JP3046318B2 (ja) * 1987-12-15 2000-05-29 ジーン・シアーズ・ピーティーワイ・リミテッド リボザイム
JP3276955B2 (ja) * 1988-09-30 2002-04-22 ジーン−トラック・システムス Ｒｎａの鋳型の末端に結合したプローブ構造およびその使用方法
NZ314629A (en) * 1991-01-17 2000-08-25 Gen Hospital Corp Use trans-splicing ribozymes to prepare medicaments for gene therapies

Also Published As

Publication number Publication date
US5589332A (en) 1996-12-31
ES2176233T3 (es) 2002-12-01
JPH08507202A (ja) 1996-08-06
EP0681613A4 (de) 1998-05-20
EP0681613A1 (de) 1995-11-15
EP1195442A3 (de) 2002-07-31
EP1195442A2 (de) 2002-04-10
AU5739694A (en) 1994-07-04
JP3595841B2 (ja) 2004-12-02
AU675482B2 (en) 1997-02-06
ATE217347T1 (de) 2002-05-15
WO1994013833A1 (en) 1994-06-23
EP0681613B1 (de) 2002-05-08
DE69331911D1 (de) 2002-06-13
JP2004000281A (ja) 2004-01-08

Similar Documents

Publication Publication Date Title
DE69331911D1 (de) Diagnose mittels signalverstärkung durch ein ribozym
NZ504818A (en) Fluorimetric detection system for nucleic acids
ATE191934T1 (de) Verfahren zur isothermer amplifikation von nukleinsäure molekülen
ATE206764T1 (de) Verfahren zum sensitiven nachweis von nukleinsäuren
CA2076750A1 (en) Nucleic acid amplification with dna-dependent rna polymerase activity of rna replicases
ATE414169T1 (de) Methoden zur detektion von nukleinsäuren unter verwendung von zymogenen und dazugehörige kits
ATE188744T1 (de) Verfahren zur erhöhung der nachweisempfindlichkeit von nukleinsäure-hybriden (target/probe)
ATE210734T1 (de) Verfahren zur quantifizierung von genomischer dna
ATE188745T1 (de) Verfahren zur detektion einer nukleinsaeure mittels einer nukleinsaeuresonde, das ein spezifisches einfangen und eine detektion auf einmal erlaubt
ATE204332T1 (de) Positionelle sequenzierung durch hybridisierung
ATE147791T1 (de) Festphasendiagnose von medizinischen konditionen
KR970010965A (ko) 핵산 증폭 방법
EP0469755A1 (de) Verfahren zur Herstellung eines Polynukleotides zur Verwendung bei Einzelprimeramplifikation
ATE339515T1 (de) Nukleinsaure vervielfaeltigungsverfahren auf basis der ramifikation-extensions-amplifizierung (ram) und der in vitro transkription
AU587188B2 (en) Nucleic acid hybridazation assay employing detectable anti- hybrid antibodies
ATE360708T1 (de) Test-streife-probesystem und verfahren zur nachweis von spezifischen nukleinsäuresequenzen
US20130244223A1 (en) Respiratory syncytial virus (rsv) viral load detection assay
Shih et al. Ribozyme amplified diagnostics
EP4299759A1 (de) Nukleinsäuredetektionsverfahren
AU2011242404B2 (en) Tethered enzyme mediated nucleic acid detection
JP2005504308A (ja) 標的分子および分子間相互作用の検出法
WO2023282857A3 (en) A method for detection of target nucleic acid using isothermal amplification
KR20070034321A (ko) 레이블 프리 표적 ｄｎａ 실시간 검출방법 및 그 장치
AU5858499A (en) Oligo nucleotides, method and kit for detecting (listeria monocytogenes) by amplifying and/or hybridizing nucleic acids
WO2002044405A3 (de) Verfahren und kit zum direkten nachweis von nukleotidsequenzen, aminosäuresequenzen oder antigenen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition